Invenra, Merck partner to discover antibodies

In July, Invenra Inc. (Madison, Wis.) and Merck & Co. Inc. (NYSE:MRK) partnered to discover antibodies against an undisclosed target from Merck. Invenra's mAbSeq, a high throughput screening technology, uses function forward screening where antibodies can be evaluated with immunotypic and biologically-relevant assays. The company's B-Body technology is a bispecific format allowing screening using mAbSeq for bispecific combinations. Invenra declined to provide additional details regarding the deal...